文献速递胃肠动力与功能性疾病

临床试验:按亚型治疗功能性消化不良与经验性质子泵抑制剂治疗的比较

Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor.
PubMed 文献 · Aliment Pharmacol Ther · 2024-12-02

这项单盲随机对照试验纳入180例功能性消化不良成人,比较按亚型治疗(餐后不适综合征用伊托必利,上腹痛综合征用埃索美拉唑,重叠型用伊托必利并在第4周维持或加用/换用埃索美拉唑)与单用埃索美拉唑经验性治疗8周的疗效与安全性。主要疗效结局达标率分别为74.4%和72.2%(p=0.74),两组各症状改善及不良反应发生率相似。结论认为按亚型初始治疗并不优于经验性PPI治疗,建议进一步开展更大样本的多中心研究验证。

要点

  • 按亚型治疗组主要疗效结局达标率为74.4%,经验性PPI组为72.2%(p=0.74)。
  • 两组9项上消化道症状改善程度相似,生活质量量表(SF-NDI)均改善但组间变化无显著差异。
  • 第8周两组不良反应发生率相似。

核心结论

  • 按亚型初始治疗功能性消化不良在8周内并不比单用经验性PPI更有效。
  • 作者建议开展更大样本的多中心研究以验证这些发现。

研究设计与样本

  • 单盲、随机对照试验,纳入功能性消化不良成人180例(中位年龄50岁,女性68.7%,餐后不适综合征56.7%),按1:1随机分为干预组和对照组。
  • 干预组按亚型治疗:上腹痛综合征用埃索美拉唑;餐后不适综合征用伊托必利;重叠型用伊托必利,维持,第4周加用和/或换用埃索美拉唑。
  • 对照组仅接受埃索美拉唑。
  • 主要疗效结局为8周内总体症状改善(主要终点:7点Likert量表最佳两级)。
  • 次要结局包括9项上消化道个体症状变化、生活质量(简明Nepean消化不良指数,SF-NDI)和不良事件。

主要发现

  • 达到主要疗效结局的患者比例在干预组为74.4%,对照组为72.2%(p=0.74)。
  • 两组的个体症状改善相似。
  • 两组的SF-NDI在治疗后均改善(p<0.001),但组间变化程度无显著差异。
  • 第8周两组不良事件发生率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者建议开展更大样本的多中心研究以验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: International guidelines recommend contrasting initial treatment strategies for functional dyspepsia (FD). AIMS: To evaluate the efficacy and safety of treatment according to subtypes, compared with empirical proton pump inhibitor (PPI), in the initial treatment of FD. METHODS: We performed a single-blinded, randomised controlled trial of adults with FD. In the intervention group (treatment according to subtype), patients were categorised into epigastric pain syndrome (treatment esomeprazole); postprandial distress syndrome (PDS; treatment itopride) and overlap (treatment itopride, maintain, add/or switch to esomeprazole at week 4). The control group received esomeprazole only. The primary efficacy outcome was the assessment of global symptom improvement (primary end point: best two points from the 7-point Likert scale) over 8 weeks. Secondary outcomes included assessment of the change in nine individual upper gastrointestinal symptoms, quality of life (Short-Form Nepean Dyspepsia Index) and adverse events. RESULTS: We randomised 180 patients (median age: 50; 68.7% female 56.7% PDS) 1:1 into intervention and control arms. The percentage of patients achieving the primary efficacy outcome were 74.4% and 72.2%, respectively (p = 0.74). The improvement of individual symptoms in both groups were similar. The SF-NDI improved after treatment in both groups (p < 0.001) but there was no significant difference in the degree of change between groups. Rates of adverse events between groups were similar at week 8. CONCLUSION: Initial treatment of FD according to subtype was not more effective than empirical PPI alone for up to 8 weeks. Further multicentre studies, with a larger sample size, are recommended to validate these findings. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04918017.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chuah KH, Loo QY, Hian WX, et al. Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor. Aliment Pharmacol Ther. 2024. PMID: 39618195. doi:10.1111/apt.18418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。